HOME > BUSINESS > Article

Text Size

small

medium

large


Rohto to Start COVID-19 Stem Cell Clinical Trial

Rohto to Start COVID-19 Stem Cell Clinical Trial

   Osaka, June 24 (Jiji Press)--Rohto Pharmaceutical Co. <4527> has said it will start in August a clinical trial for stem cell treatment of patients suffering severe symptoms of the novel coronavirus.
   The Osaka-based drug maker will examine the effectiveness of the treatment by the end of 2021, with the goal of putting the method into practical use as early as possible in 2022 or later.

To read a full story, please click here to find out how to subscribe.

BUSINESS

Aomori Tourism Information

HEADLINES

POLITICS
Toyama Governor Race to Kick Off on Oct. 8 for Voting on Oct. 25
ECONOMY
Tokyo Area Condo Supply in 2020 1st Half Drops 44% to Record Low of 7,497 Units
SPORTS
Gymnastics Women: Teramoto Steadily Recovering from Achilles Tendon Rupture
OTHER
Tokyo Coronavirus Alert Raised to Highest "Spreading" Level

AFP-JIJI PRESS NEWS JOURNAL


Photos